Related Experiment Videos
Meta-analysis of effect of statin treatment on risk of sudden death
Giacomo Levantesi1, Marco Scarano, RosaMaria Marfisi
1Consorzio Mario Negri Sud, Santa Maria Imbaro, Chieti, Italy.
Insights
Statins significantly reduce the risk of sudden cardiac death (SCD). This meta-analysis of randomized trials found statin treatment lowered SCD incidence by 19%, independent of lipid changes.
Area of Science:
- Cardiology
- Pharmacology
- Public Health
Background:
- Sudden cardiac death (SCD) remains a significant public health concern despite advances in cardiovascular disease management.
- While statins are proven effective for cardiovascular events, their specific impact on SCD is less understood.
Purpose of the Study:
- To evaluate the effect of statin therapy on the incidence of sudden cardiac death (SCD).
- To investigate whether lipid reduction mediates the potential effect of statins on SCD.
Main Methods:
- A meta-analysis of randomized controlled trials (RCTs) published between January 1966 and July 2006, identified via MEDLINE.
- Inclusion criteria included studies focusing on SCD incidence, statin vs. placebo/no treatment, randomized design, >=100 patients, and >=6 months follow-up.
- Data extraction was performed by two independent investigators.
Main Results:
- Ten RCTs involving 22,275 patients were included.
- Statin treatment was associated with a 19% reduction in SCD risk (OR 0.81, 95% CI 0.71-0.93, p=0.003).
- The benefit of statins on SCD was observed regardless of study characteristics or changes in lipid levels.
Conclusions:
- Statin therapy demonstrates a significant protective effect against sudden cardiac death.
- The risk reduction for SCD associated with statins appears independent of their lipid-lowering effects.
Abstract:
Despite significant progress in the prevention and treatment of cardiovascular disease, sudden cardiac death (SCD) is a major public health problem. Statins showed consistent benefits on cardiovascular events, but scant data were available about their effects on SCD. This meta-analysis aimed to assess the effect of statins on SCD. Additional analyses were carried out to evaluate lipid reduction as a possible mediator of the effect. Randomized controlled trials from January 1966 to July 2006 were retrieved by searching the MEDLINE database. Inclusion criteria were outcome focusing on the incidence of SCD, statin treatment compared with placebo or no treatment, randomized design, >or=100 patients enrolled, and follow-up>or=6 months. Data were independently abstracted by 2 investigators using a standardized protocol. Ten randomized controlled trials enrolling a total of 22,275 patients were included in the meta-analysis. Risks of SCD were 3% in patients receiving statins and 3.8% in control patients. Statin treatment was associated with a significant 19% risk reduction for SCD (odds ratio 0.81, 95% confidence interval 0.71 to 0.93, p=0.003). In subgroup analysis, the benefit of statins was independent from the main characteristics of the studies and changes in patient lipid levels during the study. In conclusion, our results suggest that statins decrease the risk of SCD.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:26Atherosclerosis III: Management
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:17Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
01:26Coronary Artery Disease IV: Preventive Measures
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...